Loading quotes...

Forecast

The analysts' average price target is €33.95 (+81.55%). The median is €33.95 (+81.55%).

Buy	5
Hold	4
Sell	1

News Go to news feed

Innoviva shifts growth toward specialty therapeutics

At the H.C. Wainwright conference, Innoviva explained that its business model has evolved from a licensing company into a three‑pillar healthcare platform, with Innoviva Specialty Therapeutics (IST) emerging as the main growth driver. Non‑licensing revenues now exceed traditional quarterly licensing payments, driven by products such as XACDURO, the planned launch of NUZOLVENCE and the addition of ZEVTERA. The company reports strong liquidity and investment reserves of over $1.25 billion and emphasizes that the licensing portfolio with ANORO and BREO continues to provide stable cash flow, while strategic early‑stage investments offer optional upside. » More on de.investing.com
Innoviva unveils three-pillar strategy: specialty therapeutics, COPD licenses and oral LYNX platform

Innoviva presented at the Cantor conference a growth strategy based on steady license royalties from its COPD business, a fast-growing specialty therapeutics segment (including XACDURO, GIAPREZA) and the new Nortiva/LYNX oral drug-delivery platform. IST generated over 200 million USD in revenue in the past twelve months and, according to management, is growing 40–50% annually, while Innoviva expects more than 1 billion USD in COPD license fees over the next five years. The company plans continued reinvestment, selective acquisitions and a share buyback program of up to 125 million USD, but sees the long-term need to scale new businesses like Nortiva before COPD revenues wane. International expansion and partner programs in China and emerging markets are intended to advance commercialization of XACDURO and other products. » More on de.investing.com
Innoviva: three therapies named finalists for Prix Galien USA 2026

Innoviva Specialty Therapeutics has confirmed three products — XACDURO, ZEVTERA and NUZOLVENCE — as finalists for the Prix Galien USA Award 2026 in the category “best pharmaceutical product.” XACDURO is approved for hospital- and ventilator-associated bacterial pneumonia caused by Acinetobacter, ZEVTERA is a cephalosporin approved in 2024 for Staphylococcus aureus, and NUZOLVENCE is a 2025-approved oral single-dose therapy for resistant gonorrhea. This is the third consecutive recognition of an Innoviva product by the Galien Foundation; the winners will be announced on October 29, 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2015, Innoviva has already paid €0.67 in dividends. The last payout was in September 2015.

Financials

In the last quarter, Innoviva had revenue of €104.79M and net profit of -€73.09M

(EUR)	June 2026	YoY
Revenue	104.79M	23.16%
Gross profit	79.4M	4.34%
Net profit	-73.09M	235.27%
EBITDA	187.87M	164.21%

Fundamentals

Metric	Value
Market capitalization	€1.36B
Number of shares	72.25M
52-week high/low	€22.47 - €15.94
Dividends	No
Beta	0.33
P/E ratio	4.32
PEG ratio	0.01
P/B ratio	1.25
P/S ratio	3.42

Company profile

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.